491 related articles for article (PubMed ID: 36509857)
1. Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1.
Hammoud R; Drucker DJ
Nat Rev Endocrinol; 2023 Apr; 19(4):201-216. PubMed ID: 36509857
[TBL] [Abstract][Full Text] [Related]
2. Human epicardial adipose tissue expresses glucose-dependent insulinotropic polypeptide, glucagon, and glucagon-like peptide-1 receptors as potential targets of pleiotropic therapies.
Malavazos AE; Iacobellis G; Dozio E; Basilico S; Di Vincenzo A; Dubini C; Menicanti L; Vianello E; Meregalli C; Ruocco C; Ragni M; Secchi F; Spagnolo P; Castelvecchio S; Morricone L; Buscemi S; Giordano A; Goldberger JJ; Carruba M; Cinti S; Corsi Romanelli MM; Nisoli E
Eur J Prev Cardiol; 2023 Jun; 30(8):680-693. PubMed ID: 36799940
[TBL] [Abstract][Full Text] [Related]
3. Combined GIP receptor and GLP1 receptor agonism attenuates NAFLD in male APOE∗3-Leiden.CETP mice.
Ying Z; van Eenige R; Ge X; van Marwijk C; Lambooij JM; Guigas B; Giera M; de Boer JF; Coskun T; Qu H; Wang Y; Boon MR; Rensen PCN; Kooijman S
EBioMedicine; 2023 Jul; 93():104684. PubMed ID: 37379656
[TBL] [Abstract][Full Text] [Related]
4. A comparative transcriptomic analysis of glucagon-like peptide-1 receptor- and glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus.
Smith C; Patterson-Cross R; Woodward O; Lewis J; Chiarugi D; Merkle F; Gribble F; Reimann F; Adriaenssens A
Appetite; 2022 Jul; 174():106022. PubMed ID: 35430298
[TBL] [Abstract][Full Text] [Related]
5. Incretin actions and consequences of incretin-based therapies: lessons from complementary animal models.
Renner S; Blutke A; Streckel E; Wanke R; Wolf E
J Pathol; 2016 Jan; 238(2):345-58. PubMed ID: 26455904
[TBL] [Abstract][Full Text] [Related]
6. The importance of glucose-dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide.
Gasbjerg LS; Rosenkilde MM; Meier JJ; Holst JJ; Knop FK
Diabetes Obes Metab; 2023 Nov; 25(11):3079-3092. PubMed ID: 37551549
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular biology of the GIP receptor.
Greenwell AA; Chahade JJ; Ussher JR
Peptides; 2020 Mar; 125():170228. PubMed ID: 31812593
[TBL] [Abstract][Full Text] [Related]
8. Combined glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor agonism attenuates atherosclerosis severity in APOE*3-Leiden.CETP mice.
van Eenige R; Ying Z; Tramper N; Wiebing V; Siraj Z; de Boer JF; Lambooij JM; Guigas B; Qu H; Coskun T; Boon MR; Rensen PCN; Kooijman S
Atherosclerosis; 2023 May; 372():19-31. PubMed ID: 37015151
[TBL] [Abstract][Full Text] [Related]
9. Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms.
Campbell JE
Mol Metab; 2021 Apr; 46():101139. PubMed ID: 33290902
[TBL] [Abstract][Full Text] [Related]
10. Tyr1 and Ile7 of glucose-dependent insulinotropic polypeptide (GIP) confer differential ligand selectivity toward GIP and glucagon-like peptide-1 receptors.
Moon MJ; Kim HY; Kim SG; Park J; Choi DS; Hwang JI; Seong JY
Mol Cells; 2010 Aug; 30(2):149-54. PubMed ID: 20799012
[TBL] [Abstract][Full Text] [Related]
11. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.
Nauck MA; D'Alessio DA
Cardiovasc Diabetol; 2022 Sep; 21(1):169. PubMed ID: 36050763
[TBL] [Abstract][Full Text] [Related]
12. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update.
Nauck MA; Quast DR; Wefers J; Pfeiffer AFH
Diabetes Obes Metab; 2021 Sep; 23 Suppl 3():5-29. PubMed ID: 34310013
[TBL] [Abstract][Full Text] [Related]
13. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.
Fisman EZ; Tenenbaum A
Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089
[TBL] [Abstract][Full Text] [Related]
14. Reagents and models for detecting endogenous GLP1R and GIPR.
Ast J; Broichhagen J; Hodson DJ
EBioMedicine; 2021 Dec; 74():103739. PubMed ID: 34911028
[TBL] [Abstract][Full Text] [Related]
15. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice.
Hansotia T; Drucker DJ
Regul Pept; 2005 Jun; 128(2):125-34. PubMed ID: 15780432
[TBL] [Abstract][Full Text] [Related]
16. The role of GIP in α-cells and glucagon secretion.
El K; Campbell JE
Peptides; 2020 Mar; 125():170213. PubMed ID: 31785304
[TBL] [Abstract][Full Text] [Related]
17. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
Skow MA; Bergmann NC; Knop FK
Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
[TBL] [Abstract][Full Text] [Related]
18. Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents.
Gasbjerg LS; Gabe MBN; Hartmann B; Christensen MB; Knop FK; Holst JJ; Rosenkilde MM
Peptides; 2018 Feb; 100():173-181. PubMed ID: 29412817
[TBL] [Abstract][Full Text] [Related]
19. Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors.
Zhao F; Zhou Q; Cong Z; Hang K; Zou X; Zhang C; Chen Y; Dai A; Liang A; Ming Q; Wang M; Chen LN; Xu P; Chang R; Feng W; Xia T; Zhang Y; Wu B; Yang D; Zhao L; Xu HE; Wang MW
Nat Commun; 2022 Feb; 13(1):1057. PubMed ID: 35217653
[TBL] [Abstract][Full Text] [Related]
20. GLP-1 and GIP receptor signaling in beta cells - A review of receptor interactions and co-stimulation.
Mayendraraj A; Rosenkilde MM; Gasbjerg LS
Peptides; 2022 May; 151():170749. PubMed ID: 35065096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
